Remove 2001 Remove Clinical Development Remove Regulations Remove Trials
article thumbnail

Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions

The Pharma Data

we determined the crystal structure of CD40-ligand 2 , developed a humanized version of our antibody (hu5c8, ruplizumab, or Antova®) and tested it in human trials for preventing organ transplant rejection and autoimmunity. Collaborating with a team at Biogen Inc., 175:1091-1101 (1992) 2 Karpusas, M et al., Structure. 9(4):321-9.

article thumbnail

Regulatory affairs in 2023: key trends and changes  

Drug Discovery World

Implementation of the EU Clinical Trials Regulation The way clinical trials (CTs) are conducted in the European Union (EU) underwent a major change when the Clinical Trial Regulation (CTR) EU No 536/2014 came into force on 31 January 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Achilles’ heel of cancer

Drug Discovery World

Based on this data, ezurpimtrostat completed a first-in-human clinical trial for patients with advanced cancer 5 showing sustained stabilisation in heavily pre- treated patient with mild toxicity. Recent studies have suggested that palmitoylation can regulate the expression and activity of PD-L1 6.

article thumbnail

Article FDA Thank You FDA updates set the stage for broader use of harmonized standards for safety reporting

Agency IQ

FDA updates set the stage for broader use of harmonized standards for safety reporting Though long considered a top priority by regulators, the process to standardize and harmonize the submission of individual case safety reports (ICSRs) has been slow. Periodic Benefit-Risk Evaluation Reports ).

FDA 40
article thumbnail

Human neuronal cells: possibilities in drug safety testing

Drug Target Review

1-4 This approach saves time, money, and resources, and ultimately leads to safer medicines going forward to the clinic. CNS-related issues account for nearly a quarter of failures during clinical development, a phase where consequences are high in terms of resources and patient impact. Ther Innov Regul Sci. Rockley KL.

Drugs 111